RNAi Modulation of APOB and Uses Thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsJuergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
Claims20
An iRNA agent comprising a sense strand and an antisense strand, wherein said sense strand comprises a first sequence and said antisense strand comprises a second sequence, wherein said first sequence is complementary to said second sequence, wherein said first sequence is complementary to a segment of an Apolipoprotein B (ApoB) mRNA, and wherein each strand of said iRNA agent is between 15 and 30 base pairs in length.
Dependencies are inferred from the claim text.